GATM and melanoma: The current study was performed to characterise the magnitude and temporal aspects of AGAT inactivation in PBMCs in the course of developing protracted schedules of the oral, DNA methylating agent temozolomide, which has undergone regulatory approval for treating patients with anaplastic astrocytoma on a daily × 5-day every 4-week schedule, and has also demonstrated prominent activity against other central nervous system malignancies and melanoma.